Results 131 to 140 of about 41,396 (291)

TET3‐Mediated m5C Modification of CCAT2 Accelerates Cardiac Microvascular Endothelial Cell Damage in Acute Coronary Syndrome

The Kaohsiung Journal of Medical Sciences, EarlyView.
ABSTRACT Acute coronary syndrome (ACS) is a clinical syndrome involving myocardial ischemia. This study aimed to elucidate the mechanism of TET3 in ACS‐induced CMEC damage, thereby identifying a new target for ACS treatment. The expression of TET3 in ACS patients and healthy subjects was analyzed.
Jun‐Cheng Liu, Wen‐Juan Wang, Ting‐Ting Zhang, Qi‐Chong Yang, Haliminai Dilimulati, Song‐Tao An   +5 more
wiley   +1 more source

Persistent activation of transducin by bleached rhodopsin in salamander rods. [PDF]

, 1996
The hydrolysis-resistant GTP analogue GTP-gamma-S was introduced into rods isolated from the retina of the salamander Ambystoma tigrinum to study the origin of the persistent excitation induced by intense bleaching illumination.
Cornwall, MC, Fain, GL, Matthews, HR
core  

Recurrent Respiratory Papillomatosis Foundation Position Statement on the Management of Adults With RRP

The Laryngoscope, EarlyView.
ABSTRACT Objective With regulatory approval of HPV‐specific immunotherapy for recurrent respiratory papillomatosis (RRP) and growing experience with systemic bevacizumab, a management algorithm incorporating these medical treatments is warranted. Data Sources and Methods RRP Foundation (RRPF) Key Opinion Leaders offer a proposed management algorithm ...
Simon R. Best, Aaron D. Friedman, Clark A. Rosen, Robert T. Sataloff, Laura A. Matrka, H. Steven Sims, David E. Rosow, Nabil F. Saba, David G. Lott, Adam M. Klein, Ted Mau, Milan R. Amin, Kathryn A. Wikenheiser‐Brokamp, Scott M. Norberg, Kim McClellan, Geoffrey D. Young, Clint T. Allen, on behalf of the Recurrent Respiratory Papillomatosis Foundation   +17 more
wiley   +1 more source

The evidence for using tenofovir disoproxil fumarate plus lamivudine as a nucleoside analogue backbone for the treatment of HIV. [PDF]

J Virus Erad, 2021
Waters L, Mehta V, Gogtay J, Boffito M.
europepmc   +1 more source

Multi‐Targeting Ligands as Prospective Therapeutics for Alzheimer's Disease, a Prevalent Neurodegenerative Disorder: Mechanistic Insights, Emerging Targets and Drug Discovery Campaigns

Medicinal Research Reviews, EarlyView.
ABSTRACT Alzheimer's disease (AD) is a debilitating neurodegenerative condition characterized by progressive cognitive impairment, memory deterioration, and neuronal dysfunction. Its complex pathophysiology involves multiple interlinked processes, including amyloid‐β (Aβ) aggregation, tau hyperphosphorylation, oxidative stress, neuroinflammation ...
Amandeep Thakur, Mandeep Rana, Sakshi Vanjani, Kei‐Chi Liou, Rajeev Taliyan, Kunal Nepali, Chih‐Hao Yang   +6 more
wiley   +1 more source

Nucleoside Analogue Reverse Transcriptase Inhibitors Improve Clinical Outcome in Transcriptional Active Human Parvovirus B19-Positive Patients. [PDF]

J Clin Med, 2021
Schultheiss HP, Bock T, Pietsch H, Aleshcheva G, Baumeier C, Fruhwald F, Escher F.   +6 more
europepmc   +1 more source

Selectively T cell phosphorylation activation of azvudine in the thymus tissue with immune protection effect

Acta Pharmaceutica Sinica B
Thymus is the important immune organ, responsible for T cell development and differentiation. The lower circulating T counts have been observed in patients who died from COVID-19 compared with survivors.
Ning Sheng, Rui Li, Yang Li, Zhe Wang, Lulu Wang, Yuhuan Li, Jinlan Zhang, Jiandong Jiang   +7 more
doaj   +1 more source

From HBV to MASLD Cirrhosis: Mechanistic Insights and Therapeutic Strategies

Portal Hypertension &Cirrhosis, EarlyView.
This review examines the epidemiological shift from hepatitis B virus (HBV) to metabolic dysfunction‐associated steatotic liver disease (MASLD) as the leading cause of cirrhosis globally. It highlights the distinct pathogenic mechanisms between HBV and MASLD cirrhosis and discusses evolving diagnostic tools and therapeutic strategies tailored to the ...
Hanqi Yu, Hongfan Ding, Yang Huang, Haoze Cao, Yuan Ding, Weilin Wang   +5 more
wiley   +1 more source

The Novel Nucleoside Analogue ProTide NUC-7738 Overcomes Cancer Resistance Mechanisms In Vitro and in a First-In-Human Phase I Clinical Trial. [PDF]

Clin Cancer Res, 2021
Schwenzer H, De Zan E, Elshani M, van Stiphout R, Kudsy M, Morris J, Ferrari V, Um IH, Chettle J, Kazmi F, Campo L, Easton A, Nijman S, Serpi M, Symeonides S, Plummer R, Harrison DJ, Bond G, Blagden SP.   +18 more
europepmc   +1 more source

Boron‐10 carriers and their applications in boron neutron capture therapy

Precision Radiation Oncology, EarlyView.
Summary of different types of boron drugs. Abstract Boron neutron capture therapy (BNCT) has emerged as a promising therapeutic modality in cancer treatment, demonstrating the ability to selectively eliminate cancer cells through the 10B(n,α)7Li nuclear reaction with minimal side effects on normal tissues.
Dachao Tang, Mengqi Shi, Zhichen Mao, Weiya Chen, Xiaoling Li, Xiao Yan Zhao, Zhigang Liu, Xiao Xu   +7 more
wiley   +1 more source